ISASS 2022

Visit us to discover why STIMULAN is uniquely engineered for the precision and control you demand every time
Booth #215
June 1 – June 3, 2022
Atlantis Resort, Paradise Island, Bahamas

COA/CORS/CORA 2022

Visit us to discover why STIMULAN is the perfect partner for treating infection
Booth #406
June 8 – June 10, 2022
Quebec City Convention Centre, Quebec, Canada

21 Apr 22
News
21 Apr 22
Biocomposites wins two Queen’s Awards for Enterprise in Innovation and International Trade
Innovation award recognises STIMULAN Rapid Cure as the only calcium sulfate antibiotic carrier approved for use in bone and soft tissue

International Trade award recognises Biocomposites’ outstanding continuous growth in overseas sales

Keele, UK, 21 April 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
12 Apr 22
News
12 Apr 22
Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022
Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and genex®, when mixed with antibiotics
Keele, UK, 12 April 2022,– Biocomposites, an international medical devices company that engineers, manufactures and markets…...
22 Mar 22
News
22 Mar 22
Biocomposites signs agreement with Zimmer Biomet to distribute new genex Bone Graft Substitute
genex Bone Graft Substitute upgraded with a new closed-mixing system and a comprehensive set of delivery options for U.S. market

Zimmer Biomet will exclusively distribute genex Bone Graft Substitute in the U.S.

Keele, UK, 22 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
15 Mar 22
News
15 Mar 22
Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting
Combination antibiotics released from STIMULAN completely kill antibiotic resistant biofilms

STIMULAN is the only calcium matrix antibiotic carrier approved for use in bone and soft tissue in the EU, UK, Canada, and Saudi Arabia

Keele, UK, 15 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and…...
15 Dec 21
News
15 Dec 21
A year of international growth and product advancement
Expansion into new geographies and enhanced approval for STIMULAN to treat bacterial infection
Keele, UK, 15 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and…...
7 Dec 21
News
7 Dec 21
Biocomposites signs distribution agreement with NuVasive Specialized Orthopedics to supply STIMULAN® in Germany
STIMULAN® is the first and only calcium matrix approved as an antibiotic carrier for use in bone and soft tissue • Distribution established with leader in German orthopaedic market
Keele, UK, 7 December 2021 – Biocomposites, an international medical devices company that engineers, manufactures and…...
7 Jul 21
News
7 Jul 21
Biocomposites announces new approval for STIMULAN® to treat bacterial infection
STIMULAN® when mixed with antibiotics is the only calcium matrix approved for treating bacterial infection
Keele, UK, 7 July 2021 – Biocomposites, an international medical devices company that engineers, manufactures and markets…...
STIMULAN®

The only calcium matrix approved for mixing with vancomycin, gentamicin and tobramycin for use in bone and soft tissue.

30 Mar 21
News
30 Mar 21
Biocomposites Launches Biocomposites Companion
An app that puts critical user information in the hands of healthcare professionals to ensure they harness the power of STIMULAN and genex in their surgical procedures
Keele, UK, 30 March 2021 – Biocomposites, an international medical device company that engineers, manufactures and…...
Explore our library

Our industry leading knowledge, dedication and experience is supported with over 400 peer
reviewed papers, presentations and posters.

23 Apr 20
News
23 Apr 20
Biocomposites announces new CE Mark for STIMULAN®
First calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue
Keele, UK, 23 April 2020 – Biocomposites, an international medical devices company that engineers, manufactures and…...
Pioneering calcium compounds

Innovation is at the very heart of what we do, resulting in over 100 grants and registrations.

Your specialty

Access case studies, clinical and pre-clinical papers for musculoskeletal infection, trauma and spine to see how we are innovating across a wide range of clinical applications to help surgeons and their patients.

Musculoskeletal infections

Musculoskeletal infections, including infected non-unions, osteomyelitis and periprosthetic joint infections, are one of the biggest healthcare challenges of the 21st century.

As the rapid growth of antibiotic-resistant strains and biofilms continues to outpace the development of new antibiotics and antibiotic strategies, care delivery is becoming increasingly challenging and complicated.

Spine

The popularity of spine surgery differs around the world. The number of procedures performed in the USA is double the number performed in Western Europe, Canada and Australia combined, and five times the number in the UK.

In the USA, the number of spinal fusion procedures increased by 64% between 2002 and 2014, from approximately 268,000 to 414,000. The average cost per procedure has increased from $15,868 to $28,954 over the same period and was more than $12 billion in total in 2014.

Why Biocomposites?

At Biocomposites, we are pioneering calcium compound devices to regenerate and repair bone and soft tissue. With over 30 years’ experience of manipulating the surface chemistry and crystalline properties of calcium compounds, we engineer and manufacture products at the forefront of calcium technology.

  • Singular focus
  • Proprietary technology
  • Dedicated to quality
Learn more